There is already a galaxy of life sciences data that could lead to the next cure. We’ll partner with you to make sense of it and chart a bold new path underpinned by analytics that drive decision-making.
We’ll help you deliver sustainable solutions to help more patients—new treatments for rare diseases and efficient ways to deliver therapies to larger populations.
Optimizing clinical development, operations and patient experience can shorten the gap between ideas and therapies. Predictive medicine and digital technology bring needed efficiencies to R&D activities.
Our diverse team of R&D and technology experts represents the range of backgrounds, experience and mindsets necessary to innovate—leaving legacy models and solutions behind.
- Video 1
- Video 2
“I hope that we get to a place where clinical trials are considered part of the care that a patient can partner with their doctor on—more a continuum of care.”
“Knowing my team has the ability to impact patients’ lives in a positive way is pretty incredible. At the heart of it, we’re all patients.”
“Creating this connected ecosystem that can impact a patient's overall health wasn’t possible 30 years ago. I find this innovative part quite exciting.”
“Due to AI, we're going to see exponential productivity in pharma R&D. My hunch is over the next decade we will see a reversal of Eroom’s Law.”
“We make sure there are no silos in our business. We spend time focusing on finding points of intersection where we can really add more value.”
“It’s exciting to see that we are starting to find and develop a very effective treatment in many areas to cure some really, really tough conditions.”
“Conducting innovative research that will help cure diseases while staying ethical and keeping patients at the center will help bring forward winners.”
“Biomedical research right now is undergoing a renaissance…The scientific knowledge is growing exponentially.”
“We can play a very strong role in not only catalyzing innovation, but also making sure it reaches those patients who need it the most.”
- section 1
- section 2
- section 3